HC Wainwright Issues Negative Forecast for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 10th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($0.98) per share for the quarter, down from their previous forecast of ($0.97). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($2.83) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.25) EPS, Q4 2027 earnings at $0.13 EPS, FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($3.16) EPS, FY2029 earnings at ($1.05) EPS and FY2030 earnings at $3.08 EPS.

A number of other analysts have also weighed in on ARWR. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Chardan Capital boosted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Bank of America upped their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings upgraded Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. Finally, Morgan Stanley upped their target price on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $62.38 on Thursday. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76. The firm has a market cap of $8.74 billion, a PE ratio of 40.77 and a beta of 1.21. The company’s 50 day moving average is $66.98 and its two-hundred day moving average is $44.73.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The business had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm’s revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.39) EPS.

Institutional Trading of Arrowhead Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Tsfg LLC acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $29,000. First Horizon Corp purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $32,000. Virtus Advisers LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $34,000. Finally, Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at $34,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the sale, the director directly owned 33,600 shares of the company’s stock, valued at $2,273,376. The trade was a 22.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mauro Ferrari sold 7,530 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the transaction, the director owned 69,053 shares of the company’s stock, valued at $4,833,710. This represents a 9.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 510,836 shares of company stock worth $33,603,060. 3.60% of the stock is owned by insiders.

Key Stories Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and $100 price target while raising several multi‑year EPS forecasts (notably FY2030 to $3.08). The firm’s continued Buy stance and bigger long‑term earnings lifts support a bullish growth narrative. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Positive Sentiment: Early commercial reports indicate a strong start for REDEMPLO — favourable initial uptake and revenue contribution from the product can materially improve near‑term top‑line and reduce reliance on future pipeline milestones. ARWR: Strong Start for REDEMPLO Commercialization…
• Neutral Sentiment: Short‑interest reports for February show anomalous/zero values (0 shares, NaN change) and a 0.0 days ratio — the data appear unreliable and do not provide a meaningful signal on bearish positioning. (No actionable short‑interest takeaway.)
• Negative Sentiment: Alongside the long‑term upgrades, HC Wainwright trimmed several near‑term forecasts and cut FY2026 estimates materially (FY2026 EPS lowered to -$2.83 from -$2.03), and made small downgrades to early‑2027 quarterly EPS. Those nearer‑term profit downgrades could weigh on expectations for upcoming quarters despite the Buy rating. Arrowhead (ARWR) analyst notes

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.